

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 July 2018 (12.07.2018)



(10) International Publication Number
WO 2018/127829 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) C07K 14/47 (2006.01)
A61K 38/03 (2006.01)

(21) International Application Number:

PCT/IB2018/050062

(22) International Filing Date:

04 January 2018 (04.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1700095.1 04 January 2017 (04.01.2017) GB

(71) Applicant: **APITOPE TECHNOLOGY(BRISTOL) LIMITED** [GB/GB]; Riverside Court, Beaufort Park, Chepstow Gwent NP16 5UH (GB).

(72) Inventors: **MARTIN, Keith**; C/o Apitope Technology (Bristol) Limited, Riverside Court, Beaufort Park, Chepstow Gwent NP16 5UH (GB). **JANSSON, Liselotta**; C/o Apitope Technology (Bristol) Limited, Riverside Court, Beaufort Park, Chepstow Gwent NP16 5UH (GB).

(74) Agent: **MILTON, Tamara**; D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITION

(57) Abstract: The present invention relates to a composition comprising a peptide derived from myelin basic protein (MBP) peptide for use in treating or preventing uveitis in a subject



WO 2018/127829 A1

COMPOSITION

FIELD OF THE INVENTION

5 The present invention relates to a composition which comprises a peptide or several peptides derived from Myelin Basic Protein (MBP). The composition or peptide may be useful in the prevention and/or suppression of autoimmunity, for example the prevention and/or suppression of effector T helper cells, which is useful in the treatment and/or prevention of uveitis. The invention also relates to corresponding
10 methods of treatment and uses of the peptide in the manufacture of a medicament for the treatment and/or prevention of uveitis.

BACKGROUND TO THE INVENTION

15 Uveitis describes a group of diseases associated with inflammation of the uvea. The uvea is a region of the eye located between the sclera and the retina, and includes the iris, ciliary body and choroid. The uvea provides most of the blood supply to the retina. The associated diseases are not restricted to those affecting the uvea directly, and adjacent structures such as the retina, optic nerve, lens, vitreous and
20 sclera can be affected in manifestations of uveitis.

All forms of uveitis are characterised by an inflammatory cellular infiltrate, commonly visualised using a biomicroscope. In 2010, it was estimated that 285 million people were visually impaired; of these, 39 million were blind and it was approximated that
25 10% of the cases were due to uveitis. (Global data on visual impairments, The World Health Report, WHO (2010)
<http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf>)

30 Present treatments for uveitis include the use of glucocorticoid steroids and other broad immunosuppressive agents such as methotrexate.

There is, however, a need in the art for alternative treatments for uveitis. The present invention addresses this need.

SUMMARY OF THE INVENTION

The present inventors have identified a number of peptides derived from Myelin
5 Basic Protein (MBP) which may be useful in the prevention and/or treatment of
uveitis.

The present Examples demonstrate that in an *in vivo* model of uveitis the MBP
peptides according to the invention can significantly reduce the clinical signs of
10 uveitis.

Thus, the present invention provides a composition which comprises a myelin basic
protein peptide selected from the following:

- 15 MBP 30-44 (SEQ ID NO:1);
- MBP 83-99 (SEQ ID NO:2);
- MBP 131-145 (SEQ ID NO:3); and
- MBP 140-154 (SEQ ID NO:4)

for use in treating or preventing uveitis in a subject.

20 In one aspect the composition for use in treating or preventing uveitis in a subject
may comprise MBP 30-44 (SEQ ID NO:1), 83-99 (SEQ ID NO:2), 131-145 (SEQ ID
NO:3) and 140-154 (SEQ ID NO:4), i.e. the composition may comprise a “cocktail” of
the four peptides.

25 The composition for use in treating or preventing uveitis in a subject may consist
essentially of MBP 30-44 (SEQ ID NO:1), 83-99 (SEQ ID NO:2), 131-145 (SEQ ID
NO:3) and 140-154 (SEQ ID NO:4).

The present invention also provides a method for treating or preventing uveitis in a
30 subject, wherein said method comprises the step of administration of a composition
as described herein to the subject.

It has been found that the peptides binds several MHC class II molecules including
HLA-DR and -DQ molecules and the combined use of these Apitopes provides more

widespread cover of the different Major Histocompatibility Complex (MHC) haplotypes seen in uveitis patients than therapy with a single peptide.

5 The method of treatment or prevention according to the invention may involve administration of the composition to, for example, a HLA-DQ6 or HLA-DR2 positive subject or subject expressing any other HLA type, for example DRB1, DRB3, DRB5, DQA1 or DQB1.

10 The invention encompasses use of the composition as described herein in the manufacture of a medicament for treating or preventing uveitis in a subject.

The invention also encompasses use of a composition as described herein in treating or preventing uveitis in a subject.

15 The present invention also provides a kit which comprises a myelin basic protein peptide selected from the following:

- MBP 30-44 (SEQ ID NO:1);
- MBP 83-99 (SEQ ID NO:2);
- MBP 131-145 (SEQ ID NO:3); and
- 20 MBP 140-154 (SEQ ID NO:4)

for use in the treatment of prevention of uveitis in a subject. In one aspect the composition comprises:

- MBP 30-44 (SEQ ID NO:1);
- MBP 83-99 (SEQ ID NO:2);
- 25 MBP 131-145 (SEQ ID NO:3); and
- MBP 140-154 (SEQ ID NO:4) wherein said MBP peptides may be for simultaneous, separate or sequential administration.

LIST OF FIGURES

30

Figure 1: Clinical Scores of EAU (posterior uveitis). Data are presented as Mean \pm SEM.

Figure 2: Representative TEFI Images. (A) Score 0. (B): Score 1. (C) Score 2, engorged vessels. (D) Score 3. (E) Score 4. (F) Score 5. (G) Score 6.

Figure 3: Clinical Scores of EAU (anterior uveitis). Data are presented as Mean \pm SEM. Statistical significances: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Figure 4: Representative TEFI Images. Cumulative scores of 1 – 10 due to enlarged blood vessels, increased vascularisation and infiltration.

Figure 5: Clinical Scores of EAU (posterior uveitis), huMBP and IRBP-immunised groups. Data are presented as Mean \pm SEM.

Figure 6: Clinical Scores of EAU (posterior uveitis), Area Under the Curve (AUC). Data are presented as Mean \pm SEM. Statistical significance: *** $p < 0.001$.

15

Figure 7: Anterior uveitis clinical scores (A.) and area under curve analysis (AUC) of anterior uveitis clinical scores (B.) in the huMBP + IRBP model. Data are presented as mean \pm SEM. Statistical significance: *, $p < 0.05$ and ****, $p < 0.0001$ for Cyclosporin A vs. vehicle; #, $p < 0.05$ and #####, $p < 0.0001$ for ATX peptides vs. vehicle. Bold ticks on the x axis represent ATX peptides treatments after Day 0. Grey shaded area represents time course of Cyclosporin A treatment.

20

Figure 8: Posterior uveitis clinical scores (A.) and area under the curve analysis (AUC) of posterior uveitis clinical scores (B.) in the huMBP model. Posterior uveitis clinical scores (C.) and AUC analysis of posterior uveitis clinical scores (D.) in the huMBP + IRBP model. Data are presented as mean \pm SEM. Statistical significance: *, $p < 0.05$, **, $p < 0.01$ and ****, $p < 0.0001$ for Cyclosporin A vs. vehicle; #, $p < 0.05$, ##, $p < 0.01$ and #####, $p < 0.0001$ for ATX peptides vs. vehicle. Bold ticks on the x axis represent ATX peptides treatments after Day 0. Grey shaded area represents time course of Cyclosporin A treatment.

25

30

Figure 9: Posterior uveitis onset (%) in the huMBP (A.) and huMBP + IRBP (B.) models. Statistical significance: ****, $p < 0.0001$ for Cyclosporin A vs. vehicle; #, $p <$

0.05 for ATX peptides vs. vehicle. Bold ticks on the x axis represent ATX peptides treatments after Day 0. Grey shaded area represents time course of Cyclosporin A treatment.

5

DETAILED DESCRIPTION

MYELIN BASIC PROTEIN

10 Myelin basic protein (MBP) is a protein isolatable from human brain white matter. The mature protein has 170 amino acids and the sequence is widely available in the literature (see for example: Chou *et al* (1986) J. Neurochem. 46:47-53, Figure 1; Kamholz *et al* (1986), PNAS 83:4962-4966, Figure 2; US Patent No. 5,817,629, SEQ ID NO: 1; Roth *et al* (1987), J. Neurosci. Res. 17:321-328, Figure 4; Medeviczky *et al* (2006), FEBS Letters 580:545-552, Figure 3B). Alternative splice variants/isoforms
15 of MBP may be produced due to alternative splicing of MBP (see e.g. Kamholz *supra*).

The composition for use according to the present invention comprises an MBP
20 peptide selected from:

MBP 30-44 (SEQ ID NO:1);
MBP 83-99 (SEQ ID NO:2);
MBP 131-145 (SEQ ID NO:3); and
25 MBP 140-154 (SEQ ID NO:4).

The composition may comprise MBP 30-44 (SEQ ID NO:1), 83-99 (SEQ ID NO:2), 131-145 (SEQ ID NO:3) and 140-154 (SEQ ID NO:4).

30 The composition may consist essentially of MBP 30-44 (SEQ ID NO:1), 83-99 (SEQ ID NO:2), 131-145 (SEQ ID NO:3) and 140-154 (SEQ ID NO:4).

The peptides present in the composition may consist of MBP 30-44 (SEQ ID NO:1), 83-99 (SEQ ID NO:2), 131-145 (SEQ ID NO:3) and 140-154 (SEQ ID NO:4). That is,

no other MBP peptides are present. The MBP peptides may therefore consist of SEQ ID Nos:1 to 4.

By "consisting of" is meant including, and limited to, whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and that no other elements may be present. By "consisting essentially of" is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

PEPTIDES

15

The peptides that may be used in the compositions and kits for use according to the present invention are as follows:

MBP 30-44 (SEQ ID NO:1):

20

H-Pro-Arg-His-Arg-Asp-Thr-Gly-Ile-Leu-Asp-Ser-Ile-Gly-Arg-Phe-NH₂

MBP 83-99 (SEQ ID NO:2):

25 H-Glu-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-NH₂

MBP 131-145 (SEQ ID NO:3):

H-Ala-Ser-Asp-Tyr-Lys-Ser-Ala-His-Lys-Gly-Phe-Lys-Gly-Val-Asp-NH₂

30 MBP 140-154 (SEQ ID NO:4):

H-Gly-Phe-Lys-Gly-Val-Asp-Ala-Gln-Gly-Thr-Leu-Ser-Lys-Ile-Phe-NH₂

The term "peptide" is used in the normal sense to mean a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the α -amino and carboxyl groups of adjacent amino acids. The term includes modified peptides and synthetic peptide analogues.

5

The peptide of the present invention may be made using chemical methods (Peptide Chemistry, A practical Textbook. Mikos Bodansky, Springer-Verlag, Berlin.). For example, peptides can be synthesized by solid phase techniques (Roberge JY et al (1995) Science 269: 202-204), cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, WH Freeman and Co, New York NY). Automated synthesis may be achieved, for example, using the ABI 43 1 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

10

The peptide may alternatively be made by recombinant means, or by cleavage from a longer polypeptide. For example, the peptide may be obtained by cleavage from the myelin basic protein, which may be followed by modification of one or both ends. The composition of a peptide may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure).

20

For practical purposes, there are various other characteristics which the peptide may show. For example, it is important that the peptide is sufficiently stable *in vivo* to be therapeutically useful. The half-life of the peptide *in vivo* may be at least 10 minutes, 30 minutes, 4 hours, or 24 hours.

25

The peptide may also demonstrate good bioavailability *in vivo*. The peptide may maintain a conformation *in vivo* which enables it to bind to an MHC molecule at the cell surface without undue hindrance.

30

In one aspect the composition may comprise an MBP peptide that has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% sequence identity to any one of SEQ ID NOs: 1 to 4. In a preferred aspect the peptide has at least 80%, 90%, 95%, 97% or 99% sequence identity to any one of SEQ ID NOs: 1 to 4.

Sequence identity may be assessed by any convenient method. However, for determining the degree of sequence identity between sequences, computer programs that make multiple alignments of sequences are useful, for instance Clustal W (Thompson et al., (1994) *Nucleic Acids Res.*, 22: 4673-4680). Programs that compare and align pairs of sequences, like ALIGN (Myers et al., (1988) *CABIOS*, 4: 1-17), FASTA (Pearson et al., (1988) *PNAS*, 85:2444-2448; Pearson (1990), *Methods Enzymol.*, 183: 63-98) and gapped BLAST (Altschul et al., (1997) *Nucleic Acids Res.*, 25: 3389-3402) are also useful for this purpose. Furthermore, the Dali server at the European Bioinformatics institute offers structure-based alignments of protein sequences (Holm (1993) *J. Mol. Biol.*, 233: 123-38; Holm (1995) *Trends Biochem. Sci.*, 20: 478-480; Holm (1998) *Nucleic Acid Res.*, 26: 316-9).

Multiple sequence alignments and percent identity calculations may be determined using the standard BLAST parameters, (using sequences from all organisms available, matrix Blosum 62, gap costs: existence 11, extension 1).

Alternatively, the following program and parameters may be used: Program: Align Plus 4, version 4.10 (Sci Ed Central Clone Manager Professional Suite). DNA comparison: Global comparison, Standard Linear Scoring matrix, Mismatch penalty = 2, Open gap penalty = 4, Extend gap penalty = 1. Amino acid comparison: Global comparison, BLOSUM 62 Scoring matrix.

Thus included in the scope of the invention are variants of the stated or given sequences, as long as the variant retains the functional activity of the parent i.e. the variants are functionally equivalent, in other words they have or exhibit an activity of the parent peptide as defined herein. Such variants may comprise amino acid substitutions, additions or deletions (including truncations at one or both ends) of the parent sequence e.g. of one or more e.g. 1 to 14 amino acids.

30

A substitution may be a conservative substitution. As used herein, a "conservative substitution" refers to changing amino acid identity at a given position to replace with an amino acid of approximately equivalent size, charge and/or polarity. Examples of natural conservative substitutions of amino acids include the following 8 substitution

groups (designated by the conventional one-letter code): (1) M, I, L, V; (2) F, Y, W; (3) K, R, (4) A, G; (5) S, T; (6) Q, N; (7) E, D; and (8) C, S.

5 Also included are functionally-equivalent derivatives in which one or more of the amino acids are chemically derivatised, e.g. substituted with a chemical group.

The peptides for use according to the invention can comprise portions or fragments of SEQ ID Nos1 to 4, provided that the peptide retains the required activity. Portions or fragments of SEQ ID Nos: 1 to 4 may for example be from 6 to 16 residues in length, e.g. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 residues in length.

10 The peptides for use according to the invention may be comprised within a longer peptide, i.e. a peptide which comprises any of SEQ ID Nos:1-4. The peptides for use according to the present invention may thus comprise between 8 and 30 amino acids, for example 8 to 25 amino acids, 8 to 20 amino acids, 8 to 15 amino acids or 8 to 12 amino acids. In one aspect the peptide of the present invention may thus be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length.

20 A peptide composition for use according to the invention may comprise the amino acid sequences according to the invention as described herein. In one aspect the peptide composition comprises only the amino acid sequences according to the invention as described herein, i.e. it does not comprise additional peptides other than those according to the invention.

25 The peptides may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, 30 oxalic, tartaric and maleic acid. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.

APITOPES

In an adaptive immune response, T lymphocytes are capable of recognising internal epitopes of a protein antigen. APCs take up protein antigens and degrade them into short peptide fragments. A peptide may bind to a major histocompatibility complex (MHC class II) inside the cell and be carried to the cell surface. When presented at the cell surface in conjunction with an MHC molecule, the peptide may be recognised by a T cell (via the T cell receptor (TCR), in which case the peptide is a T cell epitope.

An epitope is thus a peptide derivable from an antigen which is capable of binding to the peptide-binding groove of an MHC molecule and being recognised by a T cell.

The minimal epitope is the shortest fragment derivable from an epitope, which is capable of binding to the peptide-binding groove of an MHC class I or II molecule and being recognised by a T cell. For a given immunogenic region, it is typically possible to generate a “nested set” of overlapping peptides which act as epitopes, all of which contain the minimal epitope but differ in their flanking regions.

By the same token, it is possible to identify the minimal epitope for a particular MHC molecule: T cell combination by measuring the response to truncated peptides. For example, if a response is obtained to the peptide comprising residues 1-15 in the overlapping library, sets which are truncated at both ends (i.e. 1-14, 1-13, 1-12 etc. and 2-15, 3-15, 4-15 etc.) can be used to identify the minimal epitope.

The present inventors have previously determined that there is a link between the capacity of a peptide to bind to an MHC molecule and be presented to a T cell without further processing, and the peptide’s capacity to induce antigen-specific immune tolerance *in vivo* (WO 02/16410). If a peptide is too long to bind the peptide binding groove of an MHC molecule without further processing (e.g. trimming), or binds in an inappropriate conformation then it will not be tolerogenic *in vivo*. If, on the other hand, the peptide is of an appropriate size and conformation to bind directly to the MHC peptide binding groove and be presented to a T cell, then this peptide can be predicted to be useful for tolerance induction.

It is thus possible to investigate the tolerogenic capacity of a peptide by investigating whether it can bind to an MHC molecule and be presented to a T cell without further antigen processing *in vitro*.

5

MBP apitopes (Antigen Processing-Independent epiTOPES) are capable of binding to an MHC molecule and stimulating a response from MBP specific T cells without further antigen processing. Such apitopes can be predicted to cause tolerance to MBP, following the rule-based method described in WO 02/16410.

10

Peptides that bind to MHC class I molecules are typically 7 to 13, more usually 8 to 10 amino acids in length. The binding of the peptide is stabilised at its two ends by contacts between atoms in the main chain of the peptide and invariant sites in the peptide-binding groove of all MHC class I molecules. There are invariant sites at both ends of the groove which bind the amino and carboxy termini of the peptide. Variations in peptide length are accommodated by a kinking in the peptide backbone, often at proline or glycine residues that allow flexibility.

15

Peptides which bind to MHC class II molecules are typically between 8 and 20 amino acids in length, more usually between 10 and 17 amino acids in length, and can be longer (for example up to 40 amino acids). These peptides lie in an extended conformation along the MHC II peptide-binding groove which (unlike the MHC class I peptide-binding groove) is open at both ends. The peptide is held in place mainly by main-chain atom contacts with conserved residues that line the peptide-binding groove.

20

In a preferred embodiment, the peptide derived from MBP is capable of binding to an MHC class II molecule without further processing.

30 PORTION

The peptide of the present invention may comprise all or a portion of the MBP derived peptides shown as SEQ ID Nos: 1 to 4.

The term "portion" refers to a peptide that is derived from SEQ ID Nos: 1 to 4 and contains at least a minimal epitope, that is, the peptide is capable of binding to the peptide-binding groove of an MHC class I or II molecule, being recognised by a T cell and inducing tolerance.

5

UVEITIS

Clinically, uveitis is commonly classified as one of the following based on the part of the eye which is primarily affected: anterior uveitis, intermediate uveitis, posterior uveitis or panuveitis uveitis.

10

Anterior uveitis includes iridocyclitis and iritis. Iritis is the inflammation of the anterior chamber and iris, while iridocyclitis includes inflammation in the ciliary body.

Intermediate uveitis (pars planitis) commonly refers to vitritis – inflammation of cells in the vitreous cavity, associated with deposition of inflammatory material on the pars plana. An inflamed vitreous body, or a bleeding or a protein precipitation caused by inflammation is characterised as Intermediate uveitis. In these experiments, the intermediate uveitis symptoms are incorporated in the scoring using the TEFI images. As shown in Example 3, the score 4 (x2) making up to a total of 8 is caused by a white-out. In Figure 4, the TEFI image for the highest score reflects intermediate uveitis. In one aspect of the invention the uveitis is intermediate uveitis.

20

Posterior uveitis (chorioretinitis) is the inflammation of the retina and choroid regions.

25

Panuveitis uveitis is a general term referring to inflammation affecting all layers of the uvea.

In one aspect the uveitis is idiopathic uveitis.

30

In a preferred embodiment of the present invention the uveitis is posterior uveitis. In another aspect of the invention the uveitis is anterior uveitis. In another aspect of the invention the uveitis is intermediate uveitis.

Uveitis can also be classified as either infectious or non-infectious, with uveitis related to autoimmune diseases (i.e. primarily non-infectious) being more common in developed countries. The common animal models used to study uveitis are also driven by autoimmunity, showing a clear association between the two. It is predicted that 25-30% of uveitis is associated with systemic autoimmune or autoinflammatory diseases.

The uveitis according the present invention described herein is preferably non-infectious uveitis, even more preferably autoimmune uveitis.

TOLERANCE

T cell epitopes play a central role in the adaptive immune response to any antigen, whether self or foreign. The central role played by T cell epitopes in hypersensitivity diseases (which include allergy, autoimmune diseases and transplant rejection) has been demonstrated through the use of experimental models. It is possible to induce inflammatory or allergic diseases by injection of the autoantigen or synthetic peptides (based on the structure of T cell epitopes) in combination with adjuvant.

By contrast, it has been shown to be possible to induce immunogenic tolerance towards particular antigens by administration of peptide epitopes in soluble form. Administration of soluble peptide has been demonstrated as an effective means of inhibiting disease in experimental autoimmune encephalomyelitis (EAE – a model for multiple sclerosis (MS)) (Metzler and Wraith (1993) *Int. Immunol.* 5:1159-1165; Liu and Wraith (1995) *Int. Immunol.* 7:1255-1263; Anderton and Wraith (1998) *Eur. J. Immunol.* 28:1251-1261); and experimental models of arthritis, diabetes, and uveoretinitis (reviewed in Anderton and Wraith (1998) as above). This has also been demonstrated as a means of treating an ongoing disease in EAE (Anderton and Wraith (1998) as above).

Tolerance is the failure to respond to an antigen. Tolerance to self antigens is an essential feature of the immune system, when this is lost, autoimmune disease can result. The adaptive immune system must maintain the capacity to respond to an enormous variety of infectious agents while avoiding autoimmune attack of the self

antigens contained within its own tissues. This is controlled to a large extent by the sensitivity of immature T lymphocytes to apoptotic cell death in the thymus (central tolerance). However, not all self antigens are detected in the thymus, so death of self-reactive thymocytes remains incomplete. There are thus also mechanisms by which tolerance may be acquired by mature self-reactive T lymphocytes in the peripheral tissues (peripheral tolerance). A review of the mechanisms of central and peripheral tolerance is given in Anderton et al (1999) Immunological Reviews 169:123-137.

Available data suggests that uveitis can result from reactive T cells generated from retinal proteins, driving inflammation and mirroring the effect of a chronic infection. The composition according to the present invention is capable of inducing tolerance to self-antigens such as MBP, such that when administered to a subject, it may reinstate tolerance to the MBP protein and curtail the pathogenic immune response.

15

COMPOSITION

The composition according to the present invention may be for prophylactic or therapeutic use in patients with uveitis.

20

When administered for prophylactic use, the composition may reduce or prevent the generation of an immune response to MBP. The level of immune response is less than would be obtained if the patient had not been treated with the composition. The term "reduce" indicates that a partial reduction in immune response is observed, such as a 50%, 70%, 80% or 90% reduction in the response that would have been observed if the patient had not been treated with the composition (or in the response observed in an untreated patient over the same time-period). The term "prevent" indicates that no appreciable immune response to MBP is observed.

25

When administered for therapeutic use, the composition may suppress an already on-going immune response to MBP. The term "suppress" indicates a reduction in the level of an on-going immune response, compared to the level before peptide treatment, or the levels which would have been observed at the same time point had the treatment not been given.

30

Treatment with the composition according to the present invention may cause a reduction in level of any or all of the following:

- i) MBP autoantibodies
- 5 ii) proinflammatory CD4+ T cells specific for MBP
- iii) B cells secreting MBP autoantibodies.

Detection of all of the factors can be carried out by techniques known in the art, such as ELISA, flow cytometry etc.

10

Treatment with the composition of the present invention may also or alternatively cause anergy in CD4+ T cells specific for MBP. Anergy can be detected by, for example, subsequent challenge with MBP *in vitro*. Treatment with the composition of the present invention may cause generation of antigen-specific regulatory T cells, for example characterised by transcription factors c-Maf and NFIL3, and negative co-stimulatory molecules LAG-3, TIGIT, PD-1 and TIM-3 (see Burton *et al.* Nature Communications (2014) Article number 4741).

15

FORMULATION

20

The composition according to the invention as described herein may be prepared as an injectable, either as liquid solution or suspension; solid form suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the peptides encapsulated in liposomes. The peptide may alternatively be encapsulated in a carrier or bound to the surface of a carrier, for example a nanoparticle. The active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline (for example, phosphate-buffered saline), dextrose, glycerol, ethanol, or the like and combinations thereof.

25

30

In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents and/or pH buffering agents. Buffering salts include phosphate, citrate, acetate. Hydrochloric acid and/or sodium

hydroxide may be used for pH adjustment. For stabilisation, disaccharides may be used such as sucrose or trehalose.

5 After formulation, the composition may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried.

10 Conveniently the composition is prepared as a lyophilised (freeze-dried) powder. Lyophilisation permits long-term storage in a stabilised form. Lyophilisation procedures are well known in the art, see for example <http://www.devicelink.com/ivdt/archive/97/01/006.html>. Bulking agents are commonly used prior to freeze-drying, such as mannitol, dextran or glycine.

15 The composition may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, sublingual, intranasal, intradermal or suppository routes or implanting (e.g. using slow release molecules or devices).

20 The composition may advantageously be administered via intranasal, subcutaneous or intradermal routes. In a preferred embodiment administration is intradermal.

25 The method and pharmaceutical composition for use according to the invention may be used to treat a human subject. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.

30 The composition as described herein is typically administered in an "effective amount"; that is, an amount effective to elicit any one or more inter alia of a therapeutic or prophylactic effect. Persons skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount to include in a pharmaceutical composition or to be administered for the desired outcome. In general, composition as disclosed herein can be administered in a manner compatible with the route of administration and physical characteristics of the recipient (including health status) and in such a way that it elicits the desired effect(s)

(i.e. therapeutically effective and/or protective). For example, the appropriate dosage of a composition may depend on a variety of factors including, but not limited to, a subject's physical characteristics (e.g., age, weight, sex), and other factors that may be recognized by persons skilled in the art. Other illustrative examples of general considerations that may be considered when determining, for example, an appropriate dosage of the compositions are discussed by Gennaro (2000, "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; and Gilman et al., (Eds), (1990), "Goodman And Gilman's: The Pharmacological Bases of Therapeutics", Pergamon Press).

10

It is expected that the amount will fall in a relatively broad range that can be determined through methods known to persons skilled in the art, having regard to some of the considerations outlined above.

15 The peptide and composition of the invention may be used to treat a human subject. The subject according to the invention preferably has posterior uveitis. The subject may have T cells specific to MBP.

In a preferred embodiment a "dose escalation" protocol may be followed, where a plurality of doses is given to the patient in ascending concentrations. Such an approach has been used, for example, for phospholipase A2 peptides in immunotherapeutic applications against bee venom allergy (Müller et al (1998) J. Allergy Clin Immunol. 101:747-754 and Akdis et al (1998) J. Clin. Invest. 102:98-106).

25

KIT

Peptides derived from MBP may be administered together, in the form of a mixed composition or cocktail. However, there may be circumstances in which it is preferable to provide the peptides separately in the form of a kit, for simultaneous, separate, sequential or combined administration.

30

For example, the kit may comprise the three peptides in separate containers. The contents of the containers may or may not be combined prior to administration.

The kit may also comprise mixing and/or administration means (for example a vapouriser for intranasal administration; or a syringe and needle or other medical device for subcutaneous/intradermal dosing). The kit may also comprise instructions for use.

5

The composition/kit may be used to suppress or prevent the production of MBP autoantibodies *in vivo*. In particular, the composition/kit may be used to treat and/or prevent uveitis in a subject.

10 ANIMAL MODEL

The present invention also encompasses an animal model of uveitis. As discussed in the Examples, the animal model according to the invention provides the advantage that uveitis is induced without induction of encephalomyelitis (EAE).

15

Thus in a further aspect the present invention provides an animal model for uveitis, wherein the animal comprises increased levels of myelin basic protein (MBP) and interphotoreceptor retinoid binding protein (IRBP) compared to a control animal.

20 The term “increased levels of MBP and IRBP” is intended to encompass an increased level of any of the full length MBP or IRBP sequence, for example MBP or IRBP peptides.

In one aspect the MBP is from, or is derived from, human or guinea pig (gpMBP).

25 The sequences of human and guinea pig MBP are set out below:

Human MBP (UniProtKB entry P02686 – full length human MBP sequence)

30 MGNHAGKRELNAEKASTNSETNRGESEKRNRLGELSRRTTSEDNEVFGEDANQNGTSSQ
DTAVTDSKRTADPKNAWQDAHPADPGSRPHLIRLFSRDAPGREDNTFKDRPSEDELQTI
QEDSAATSESLDVMASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFG
GDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVTPRTPPPSQGKG
RGLSLRFSWGAEGQRPGFGYGGRASDYKSAHKGFGVDAQGTLISKIFKLGGDRSRSGSP
MARR (SEQ ID NO: 5)

35 Other isoforms of MBP are also known, for example UniProtKB P02686-3, P02686-4, P02686-5 and P02686-6.

Guinea pig MBP (UniProtKB entry P25188)

ASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFGSDRAAPKRGSGKDS
 HHAARTTHYGSLPQKSQRSQDENPVVHFFKNIVTPRTPPPSQGKGRGLSLSRFSWGAEGQ
 5 KPGFGYGGRADYKSKGFKGAHDAQGTLKIFKLGGDRSRSGSPMARR (SEQ ID NO: 6)

In one aspect of the invention the IRBP is human IRBP, or is derived from human IRBP. The sequence of human IRBP is set out below (UniProtKB entry P10745):

10 MMREWWLLMSVLLCGLAGPHTLHFQPSLVLDMAKVLLDNYCFPENLLGMQEAIQQAISHE
 ILSISDPQTLASVLTAGVQSSLNDRPRLVISYEPSTPEPPPQVPALTSLSEEELLAWLQRG
 LRHEVLEGNVGYLRVDSVPGQEVLSMMGEFLVAHVWGNLMGTSALVLDLRHCTGGQVSGI
 PYIISYLHPGNTILHVDTIYNRPSNTTTEIWTLPQVLGERYGADKDVVLTSSQTRGVAE
 15 DIAHILKQMRRAIVVGERTGGGALDLRKLRIGESDFFFTVPVSRSLGPLGGGSQTWEGSG
 VLPCVGTPAEQALEKALAILTLRSALPGVVHCLQEVLKDYITLVDRVPTLLQHLASMDFS
 TVVSEEDLVTKLNAGLQAASEDPRLLVRAIGPTETPSWPAPDAAAEDSPGVAPELPEDEA
 IRQALVDSVVFQVSVLPGNVGYLRFDSDASVGLVLPYVLRQVWEPLQDTEHLIMDLRH
 NPGGPSSAVPLLLSYFQGPEAGPVHLFTTYDRRTNITQEHFSHMELPGPRYSTQRGVYLL
 20 TSHRTATAAEFFAFLMQSLGWATLVGEITAGNLLHTRTVPLLDTPEGSLALTVPVLTFFID
 NHGEAWLGGGVVDPDAIVLAAEEALDKAQEVLEFHQSLGALVEGTGHLLAEHYARPEVVGQT
 SALLRAKLAQGAYRTAVDLESASQLTADLQEVSGDHRLLVFHSPGELVVEEAPPPPPAV
 PSPEELTYLIEALFKTEVLPGQLGYLRFDAMAELETVKAAGPQLVRLVWQQLVDTAALVI
 DLRYNPGSYSTAIPLLCSYFFEAEPQRHLYSVFDRATSKVTEVWTLQVAGQRYGSHKDL
 25 YILMSHTSGSAAEFAHTMQDLQRATVIGEPTAGGALSVMGIYQVSSPLYASMPQAMMS
 ATTKAWDLAGVEPDTVPMSEALSIAQDIVALRAKVPTVLQTAGKLVADNYASAELGAK
 MATKLSGLQSRYSRPTSEVALAEILGADLQMLSGDPLKAAHIPENAKDRIPGIVPMQIP
 SPEVFEELIKFSFHTNVLEDNIGYLRFDMGDCELLTQVSRLLVEHIWKKIMHTDAMIID
 MRFNIGGPTSSIPILCSYFFDEGPPVLLDKIYSRPDDSVSELWTHAQVVGERYGSKKSMV
 30 ILTSSVTAGTAAEFTYIMKRLGRALVIGEVTSGGCQPPQTYHVDDTNLYLTIPTARSVGA
 SDGSSWEGVGVTPHVVPAAEEALARAKEMLQHNQLRVKRSPLQDHL (SEQ ID NO: 7)

In one aspect the IRBP is bovine IRBP (SEQ ID NO: 8) (UniProtKB entry P12661):

35	MVRKWALLLP	MLLCGLTGPA	HLFQPSLVLE	MAQVLLDNYC	FPENLMGMQG
	60	70	80	90	100
	AIEQAIKSQE	ILSISDPQTL	AHVLTAGVQS	SLNDPRLVIS	YEPSTLEAPP
	110	120	130	140	150
	RAPAVTNLTL	EEIIAGLQDG	LRHEILEGNV	GYLRVDDIPG	QEVMSKLRSF
	160	170	180	190	200
40	LVANVWRKLV	NTSALVLDLR	HCTGGHVSGI	PYVISYLHPG	STVSHVDTVY
	210	220	230	240	250
	DRPSNTTTEI	WTLPEALGK	YSADKDVVVL	TSSRTGGVAE	DIAYILKQMR
	260	270	280	290	300
	RAIVVGERTV	GGALNLQKLR	VGQSDFFLTV	PVSRSLGPLG	EGSQTWEGSG
45	310	320	330	340	350
	VLPCVGTPAE	QALEKALAVL	MLRRALPGVI	QRLQEALREY	YTLVDRVPAL
	360	370	380	390	400
	LSHLAAMDLS	SVVSEDDLVT	KLNAGLQAVS	EDPRLQVQVV	RPKEASSGPE
	410	420	430	440	450
50	EEAEPEPEAV	PEVPEDEAVR	RALVDSVVFQV	SVLPGNVGYL	RFDSFADASV
	460	470	480	490	500
	LEVLGPYILH	QVWEPLQDTE	HLIMDLRQNP	GGPSSAVPLL	LSYFQSPDAS
	510	520	530	540	550
	PVRLFSTYDR	RTNITREHFS	QTELLGRPYG	TQRGVYLLTS	HRTATAAEEL

	560	570	580	590	600
	AFLMQSLGWA	TLVGEITAGS	LLHTHTVSLL	ETPEGGLALT	VPVLTFFIDNH
	610	620	630	640	650
5	GECWLGGGVV	PDAIVLAEEA	LDRAQEVLEF	HRSLGELVEG	TGRLLLEAHYA
	660	670	680	690	700
	RPEVVGQMG	LLRAKLAQGA	YRTAVDLESL	ASQLTADLQE	MSGDHRLLVF
	710	720	730	740	750
	HSPGEMVAEE	APPPPPVVPS	PEELSYLIEA	LFKTEVLPGQ	LGYLRFDAMA
10	760	770	780	790	800
	ELETVKAVGP	QLVQLVWQKL	VDTAALVVDL	RYNPGSYSTA	VPLLCSYFFE
	810	820	830	840	850
	AEPRRHLYSV	FDRATSRVTE	VWTLPHVTGQ	RYGSHKDLVY	LVSHTSGSAA
	860	870	880	890	900
15	EAFAHMQDL	QRATIIIGEPT	AGGALSVDGIY	QVGSSALYAS	MPTQMAMSAS
	910	920	930	940	950
	TGEAWDLAGV	EPDITVPMVS	ALSTARDIVT	LRKVPTVLQ	TAGKLVADNY
	960	970	980	990	1000
	ASPGLGVKMA	AELSGLQSRV	ARVTSEAALA	ELLQADLQVL	SGDPHLKTAH
	1010	1020	1030	1040	1050
20	IPEDAKDRIP	GIVPMQIPSP	EVFEDLIKFS	FHTNVLEGNV	GYLRFDMFGD
	1060	1070	1080	1090	1100
	CELLTQVSEL	LVEHVWKKIV	HTDALIVDMR	FNIGGPTSSI	SALCSYFFDE
	1110	1120	1130	1140	1150
25	GPPILLDKIY	NRPNSVSEL	WTLSQLEGER	YGSKKSMVIL	TSTLTAGAAE
	1160	1170	1180	1190	1200
	EFTYIMKRLG	RALVIGEVTS	GGCQPPQTYH	VDDTDLYLTI	PTARSVGAAD
	1210	1220	1230	1240	1250
	GSSWEGVGVV	PDVAVPAEAA	LTRAQEMLQH	TPLRARRSPR	LHGRRKGHHR
	1260	1270	1280		
30	QSQGRAGSLG	RNQGVRPEV	LTEAPSGQKR	GLLQCG	

In one aspect of the invention the IRBP is a peptide derived from IRBP, preferably IRBP1177-1191 ADGSSWEGVGVVDPDV (SEQ ID NO: 9).

35 The level of MBP and IRBP is increased over a suitable control animal, for example an animal to which exogenous or transgenic MBP and IRBP has not been administered.

The level of MBP and IRBP may be increased in the animal by any suitable means.
 40 For example, this may be by immunising the animal with MBP and IRBP, as described in the present Examples.

Alternatively, said increase may be achieved by administering one or more vectors comprising one or more nucleic acid molecules which encode MBP and/or IRBP. In a
 45 preferred embodiment the vector is a viral vector.

In a further embodiment, the invention provides a method for producing an animal model of uveitis, said method comprising increasing the level of MBP and IRBP in an animal.

- 5 In a preferred embodiment the method comprises increasing the level of MBP and IRBP by administering MBP and IRBP to the animal, that is by immunising the animal with MBP and IRBP e.g. as described in the present Examples.

10 The animal model has features which are relevant to uveitis. For example, in the animal model, clinical signs of uveitis may be increased compared to equivalent control animals in which the levels of MBP and IRBP are not increased.

The MBP and/or IRBP may be human MBP and/or IRBP.

- 15 The MBP or IRBP may be a part or fragment or portion of MBP or IRBP, provided that the required function is retained in the animal model. In one aspect the IRBP may be the IRBP1177-1191 peptide (ADGSSWEGVGVVDPV (SEQ ID NO: 9) - also referred to as R16).

- 20 The MBP and/or IRBP may be administered to the animal in any suitable manner, for example oral, intravenous (where water soluble), intramuscular, subcutaneous, sublingual, intranasal, intradermal or suppository routes or implanting (e.g. using slow release molecules).

- 25 In one aspect administration is sub-cutaneous.

A suitable dose of the MBP that is administered to the animal may be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 μ g. In one aspect about 100 μ g of MBP is administered.

30

A suitable dose of the IRBP that is administered to the animal may be about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90 or 100 μ g. In one aspect about 20 μ g of IRBP is administered.

In one aspect the MBP and/or IRBP is administered with an adjuvant, for example Freund's adjuvant.

5 A nucleic acid encoding MBP and/or IRBP may be provided using methods which are well known in the art, for example based on the MBP and/or IRBP sequences described herein.

10 The nucleic acid may be natural, synthetic or recombinant. It may be double or single stranded, it may be DNA or RNA or combinations thereof. It may, for example, be cDNA, a PCR product, genomic sequence or mRNA.

The nucleotide sequence may be codon optimised for production in the host/host cell of choice.

15 Delivery of the nucleotide sequence encoding MBP and/or IRBP may be mediated by viral infection. Suitable viral vectors are well known in the art. For example the viral vector may be an adenovirus, retrovirus or lentivirus.

20 Production of the animal model may comprise multiple administrations of the vector.

The vector, for example adenovirus, may be administered at 3 week intervals. For example, the vector may be administered at an interval of 18-25, 18-23, 19-23 or 20-22 days. The vector may be administered at an interval of 20, 21 or 22 days.

25 The animal model may comprise administering the adenovirus vector on at least two occasions. For example the adenovirus vector may be administered on two or three occasions.

30 The vector, for example adenovirus, may be administered at a dose of 10^8 to 10^{11} viral particles per administration. In particular, the adenovirus may be administered at a dose of 10^9 to 10^{11} viral particles per administration. The adenovirus may be administered at a dose of 10^9 viral particles per administration.

The vector may be administered by any suitable means. For example, in the case of an adenoviral vector, the vector may be administered by intramuscular injection.

5 The animal may be a mammal. For example the animal may be a mouse, rat, rabbit, guinea pig or primate. Preferably, the animal is a rat.

In one embodiment the animal is a Lewis rat, preferably a female Lewis rat.

10 By way of example, the model described in the present Examples was generated by administration by subcutaneous injection with 200 microliters of an emulsion containing 20 micrograms of IRBP1177-1191 and 100 micrograms of human (huMBP) or guinea pig Myelin Basic Protein (gpMBP) in incomplete Freund's adjuvant supplemented with 5 mg/ml Mycobacterium Tuberculosis H37Ra. As discussed herein, the model according to the invention provides the advantage that
15 it induces uveitis with marginal induction of encephalomyelitis.

The invention will now be described with reference to the following Examples.

EXAMPLES

Example 1

20 This study aimed at studying the effect, in Lewis rats, of immunisations with guinea pig myelin basic protein (gpMBP), human myelin basic protein (huMBP) and/or interphotoreceptor retinoid-binding protein with regard to development of encephalomyelitis (EAE) and/or uveitis (EAU).

25 Experimental outline

Adult female Lewis rats were randomly allocated to experimental groups and allowed to acclimatise for one week. On Day 0, animals were administered by subcutaneous injection with 200 microliters of an emulsion containing 20 micrograms of IRBP1177-1191 (Cambridge Bioscience, UK) and/or 100 micrograms of human (Fitzgerald
30 Industries International, MA, US) or guinea pig Myelin Basic Protein (gpMBP) in incomplete Freund's adjuvant (Sigma, UK) supplemented with 5 mg/ml Mycobacterium Tuberculosis H37Ra (500 µg per rat) (Becton Dickenson, UK). From

Day 0 until the end of the experiment, animals were weighed daily. From Day 0 until the end of the experiment, animals were scored daily for clinical signs of experimental autoimmune encephalomyelitis to include limpness, paresis and/or paralysis of the tail, hind limbs and/or front limbs. From Day 0 until the end of the experiment, animals were scored twice weekly for clinical signs of uveitis. On Day 21 (Groups 1, 2 and 3) or Day 28 (Groups 4 and 5), animals were culled and the following samples were dissected out and stored in tissue fixative for optional histopathology analysis: brain, spinal cord, right and left eyes.

10 **Treatment Groups and Dosages**

Groups 1, 2 and 3 are n=8 per group

Groups 4 and 5 are n=14 per group

	Group	Antigenic Challenge	Necropsy
1	IRBP	Day 0: 200 µl emulsion containing 20 µg IRBP in CFA 5 mg/ml <i>Mycobacterium Tuberculosis*</i>	Day 21
2	gpMBP	Day 0: 200 µl emulsion containing 100 µg gpMBP in CFA 5 mg/ml <i>Mycobacterium Tuberculosis*</i>	
3	IRBP & gpMBP	Day 0: 200 µl emulsion containing 20 µg IRBP and 100 µg gpMBP in CFA 5 mg/ml <i>Mycobacterium Tuberculosis*</i>	
4	huMBP	Day 0: 200 µl emulsion containing 100 µg huMBP in CFA 5 mg/ml <i>Mycobacterium Tuberculosis*</i>	Day 28
5	IRBP & huMBP	Day 0: 200 µl emulsion containing 20 µg IRBP and 100 µg huMBP in CFA 5 mg/ml <i>Mycobacterium Tuberculosis*</i>	

n/a: not applicable, IRBP: interphotoreceptor binding protein, gpMBP: guinea pig myelin basic protein, huMBP: human myelin basic protein, CFA: complete Freund's adjuvant, SC: subcutaneous injection, *500 µg per rat

15

Readouts

Non-specific clinical observations

From Day 0 until the end of the experiment, animals were checked daily for non-specific clinical signs to include abnormal posture (hunched), abnormal coat condition (piloerection) and abnormal activity levels (reduced or increased activity).

Bodyweights

From Day 0 until the end of the experiment, animals were weighed daily.

10 Clinical Scores (Uveitis)

From Day 0 until the end of the experiment, animals were visually scored twice per week for clinical signs of anterior uveitis using the following scoring system. The maximum possible score was 3. Data were graphed (Mean \pm SEM).

	Description
0	Normal
1	Slight iris vessel dilation and thickened iris stroma, a few scattered inflammatory cells
2	Engorged blood vessels in the iris, abnormal pupil contraction
3	Hazy anterior chamber

15

From Day 0 until the end of the experiment, animals were scored twice per week for clinical signs of intermediate and posterior uveitis. Retinal images were captured using TEFI in non-anaesthetised but restrained animals following pupil dilatation using Tropicamide 1% then Phenylephrine hydrochloride 2.5%. Retinal images were scored using the following system. The maximum possible score was 6. Data were graphed (Mean \pm SEM). TEFI images displays symptoms of both intermediate and posterior uveitis.

20

	Description
	Retinal vessels
1	1 vessel engorged
2	More than 1 vessel engorged
3	All main vessels engorged
	Retinal tissue Infiltration
1	1-2 small areas of retinal damage
2	3+ small areas or 1+ large area

3 Not visible (white-out or severe detachment) (caused by
e.g.vitreous body inflammation or bleeding)

Results

Non-specific clinical observations

5 From Day 0 until the end of the experiment, animals did not show any non-specific
clinical signs such as abnormal posture (hunched), abnormal coat condition
(piloerection) or abnormal activity levels (reduced or increased activity). In animals
administered with gpMBP, a significant bodyweight loss was observed from Day 11
until the end of the experiment on Day 21 when compared to the IRBP-administered
group ($p < 0.0001$).

10

In animals administered with IRBP and gpMBP, a significant bodyweight loss was
observed from Day 11 until the end of the experiment on Day 21 when compared to
the IRBP-administered group ($p < 0.05$ on Day 11, $p < 0.001$ on Day 12, $p < 0.0001$
from Day 13 until Day 20 and $p < 0.001$ on Day 21). There was no difference in
15 bodyweight loss between animals administered with gpMBP alone and animals
administered with gpMBP and IRBP. There was no significant bodyweight loss
observed in animals administered with IRBP alone, human MBP or human MBP with
IRBP.

20 Clinical scores - Uveitis

Animals with an average score for both eyes greater than 0.5 on at least two
consecutive TEFI sessions (see Figure 2) or a score greater than 1.0 on any
occasion were considered to have developed clinical signs of posterior uveitis.

Based on this criterion, the incidence of EAU was:

Group	Incidence	Onset (Day)	Maximum Score
IRBP	100% (8/8)	10.5 ± 0.5	5.6 ± 0.3
gpMBP	50% (4/8)	11.5 ± 0.5	1.1 ± 0.2
gpMBP and IRBP	100% (8/8)	9.0 ± 0.8	4.9 ± 0.4
huMBP	100% (14/14)	10.2 ± 0.7	4.1 ± 0.5
huMBP and IRBP	100% (14/14)	9.9 ± 0.5	5.0 ± 0.3

Due to the lack of pigmentation in the retina of Lewis rats, the scoring system below was used. This is due to the inability to identify areas of infiltration causing haziness and cuffing on a pale background. Inflammation of the optic disc could not be clearly identified and was not therefore scored, also, no structural damage was observed.

5 Infiltration of retinal vessels could be identified by engorged appearance on a scale of 0 - 3, mild to severe. Retinal inflammation was identified by the appearance of small to large areas of redness caused by increase in vascularisation also on a scale of 0 – 3, giving a total possible score of 6.

Description	
Retinal vessels	
1	1 vessel engorged
2	More than 1 vessel engorged
3	All main vessels engorged
Retinal tissue Infiltration	
1	1-2 small areas of retinal damage
2	3+ small areas or 1+ large area
3	Not visible (white-out or severe detachment)

10

The incidence of clinical signs of posterior uveitis was maximal in all experimental groups administered with IRBP, either alone or in combination with gpMBP or huMBP. Clinical signs of EAU were also observed in 50% of the gpMBP-
 15 administered animals and in 100% of the huMBP-administered animals in absence of IRBP (see Figure 1).

The onset of clinical signs of EAU did not differ statistically between experimental groups.

20

The severity of the clinical signs of EAU was significantly lower in the gpMBP-administered animals when compared to the experimental group administered with IRBP ($p < 0.001$), IRBP and gpMBP ($p < 0.01$), IRBP and huMBP ($p < 0.01$) or huMBP ($p < 0.05$).

25

Clinical signs of anterior uveitis were also observed during the experiment.

Data collected until Day 21 were analysed by two-way ANOVA followed by Dunnett's post-test for multiple comparisons between experimental groups.

In IRBP-administered animals, clinical signs were observed from Day 11. Signs were significantly higher than in the gpMBP-administered group on Day 11, Day 14 and
5 Day 18 ($p < 0.0001$) (see Figure 3).

In IRBP & gpMBP-administered animals, signs of anterior uveitis were also observed from Day 11 ($p < 0.0001$ on Day 11, $p < 0.01$ on Day 14 and Day 18 and $p < 0.05$ on
10 Day 21) when compared to the gpMBP-administered group.

In IRBP & huMBP-administered animals, signs of anterior uveitis were observed on Day 11 and Day 14 ($p < 0.0001$) when compared to the gpMBP-administered group.

In huMBP-administered animals, signs of anterior uveitis were observed on Day 14
15 ($p < 0.0001$) and Day 18 ($p < 0.01$) when compared to the gp-MBP administered group.

Guinea pig MBP may induce Experimental autoimmune encephalomyelitis (EAE) in Lewis rats, a model for multiple sclerosis (MS). In this experiment, severe EAE was
20 developed in Lewis rats immunised with gpMBP alone (incidence 8/8 rats; mean max score 3.5) or in combination with IRBP peptide (incidence 8/8 rats; mean max score 3.9) using the scoring system for paralytic symptoms: 0) no abnormality, (0.5) partial tail limpness, (1) complete tail limpness, (2) one hind limb paresis, (2.5) two hind limbs paresis, (3) one hind limb paralysis, (4) two hind limb paralysis, (5)
25 incontinence and (6) moribund. With difference to the gpMBP immunised rats, very mild symptoms were displayed in the other groups: Immunised with IRBP alone (incidence 2/8, mean max score 1.0); huMBP immunised (incidence 3/14, mean max score 1.0) and huMBP in combination with IRBP peptide (incidence 3/14, mean max score 1.0).

30

Conclusion

Administration of huMBP resulted in signs of both anterior and posterior uveitis.

When administered at the same time as IRBP clinical signs of both anterior and intermediate/posterior uveitis were increased and provided a robust model for testing for efficacy against autoimmune uveitis.

- 5 With addition of the very low incidence and severity of EAE developed after immunisation with human MBP it was decided to use the model of uveitis involving immunisation with human MBP alone or with the addition of the IRBP peptide for studying the effects of the MBP peptides according to the present invention, as described in Example 2.

10 **Example 2**

This example details studies of the effect of ATX-UV-3 in a Lewis rat model of human myelin basic protein (huMBP) and interphotoreceptor retinoid-binding protein (IRBP)-induced uveitis, as described in Example 1.

- 15 ATX-UV-3 comprises:

MBP 30-44 (SEQ ID NO:1);

MBP 83-99 (SEQ ID NO:2);

MBP 131-145 (SEQ ID NO:3); and

- 20 MBP 140-154 (SEQ ID NO:4)

Methods

Experimental outline

- Adult female Lewis rats were randomly allocated to experimental groups and allowed to acclimatise for one week. On Day 0, animals were administered by subcutaneous
25 injection with 200 microliters of an emulsion containing 100 micrograms of human Myelin Basic Protein (MBP) (Fitzgerald Industries International, MA, US) in incomplete Freund's adjuvant (Sigma, UK) supplemented with 5 mg/ml Mycobacterium Tuberculosis H37Ra (500 µg per rat)(Becton Dickenson, UK) and 20 micrograms of IRBP 1177-1191 (Cambridge Bioscience, UK). From Day 0 until the
30 end of the experiment, animals were scored twice weekly for clinical signs of uveitis.

On Day 21, clinical scores were analysed and the study was extended to Day 35. On Day 35, animals were culled and eyes (right and left) were dissected out and stored in tissue fixative for histopathology analysis.

Table 1: Treatment Groups and Dosages

5 (All groups are n=12)

	Group	Treatment			Disease Induction
		Dose	Route	Regimen	
1	Vehicle	n/a	SC	Days -8, -6 and -4	Day 0: 100 µg huMBP and 20 µg IRBP
2	ATX -UV-3	100 µg	SC	Days -8, -6 and -4	

n/a: not applicable, IRBP: interphotoreceptor binding protein, huMBP: human myelin basic protein, SC: subcutaneous injection.

10 *Non-specific clinical observations*

From Day 0 until the end of the experiment, animals were checked daily for non-specific clinical signs to include abnormal posture (hunched), abnormal coat condition (piloerection) and abnormal activity levels (reduced or increased activity).

Clinical Scores (Uveitis)

15 From Day 0 until the end of the experiment, animals were scored twice per week for clinical signs of ocular inflammation (anterior uveitis) using the following scoring system: (0) normal, (1) slight iris vessel dilation and thickened iris stroma, a few scattered inflammatory cells, or both, (2) engorged blood vessels in the iris, abnormal pupil contraction and (3) hazy anterior chamber. Data were graphed (Mean
20 ± SEM).

Table 2: Anterior uveitis scoring:

Score	Description
0	Normal
1	Slight iris vessel dilation and thickened iris stroma, a few

	scattered inflammatory cells
2	Engorged blood vessels in the iris, abnormal pupil contraction
3	Hazy anterior chamber

From Day 0 until the end of the experiment, animals were scored twice per week for clinical signs of uveitis. Retinal images were captured using TEFI in non-anaesthetised but restrained animals following pupil dilatation using Tropicamide 1% then Phenylephrine hydrochloride 2.5%. Retinal images were scored using the modified scoring system described below with a maximum possible score of 10. Data were graphed (Mean \pm SEM).

Table 3: Intermediate/posterior uveitis scoring:

Score	Criteria
Retinal vessels	
1	1 vessel engorged
2	More than 1 vessel engorged
3	All main vessels engorged
4	Not visible due to 'white-out' ¹
Retinal tissue Infiltration	
1	1-2 small areas of retinal damage
2	3+ small areas or 1+ large area
3	Widespread damage
4	Not visible (white-out or severe detachment)
Structural damage	
1	Retinal detachment with folding
2	Not visible (white-out or severe detachment)

¹ also refers to intermediate uveitis

Results

Non-specific clinical observations

From Day 0 until the end of the experiment, animals did not show any non-specific clinical signs such as abnormal posture (hunched), abnormal coat condition (piloerection) or abnormal activity levels (reduced or increased activity).

Clinical scores (Uveitis)

5 Posterior uveitis

Animals with an average score for both eyes greater than 0.5 on at least two consecutive TEFI sessions or a score greater than 1.0 on any occasion were considered to have developed clinical signs of posterior uveitis (Figure 5).

10 Table 4: Incidence of posterior/intermediate EAU:

Group	Incidence	Onset (Day)	Maximum Score
huMBP/IRBP, Vehicle	100% (12/12)	8.3 ± 0.4	7.3 ± 0.7
huMBP/IRBP, ATX-UV-3	100% (12/12)	9.8 ± 1.0	6.0 ± 0.5

15 Clinical scores were analysed by two-way ANOVA followed by Tukey's post-test for multiple comparisons between experimental groups on each experimental day (Figure 5).

In the huMBP and IRBP-challenged groups, ATX peptide significantly reduced the clinical scores when compared to the vehicle-treated group on Day 10 ($p < 0.0001$), Day 14 ($p < 0.01$) and Day 17 ($p < 0.05$).

20

Clinical scores were further analysed by calculating Area Under the Curve (AUC) values and comparing AUC for each experimental group by one-way ANOVA followed by Sidak's post-test for multiple comparisons between all experimental groups (Figure 6).

25

In the huMBP and IRBP-challenged groups, ATX peptide significantly reduced the clinical scores when compared to the vehicle-treated group ($p < 0.001$).

Example 3

- 5 A further study was carried out to investigate the efficacy of ATX-UV-3 in an animal model of uveitis. Cyclosporin A was included as a positive control. (A high dose of Cyclosporin A was used which would not be a physiological dose for humans but was chosen for the purpose of validating the model.)

10 Experimental outline

Adult female Lewis rats were randomly allocated to experimental groups and allowed to acclimatise for one week. Treatments were administered according to the schedule below. On Day 0, animals were administered by subcutaneous injection with 200 microliters of an emulsion containing 100 micrograms of human Myelin Basic Protein (MBP) in incomplete Freund's adjuvant supplemented with 5 mg/ml Mycobacterium Tuberculosis H37Ra (500 μg per rat) and/or 20 micrograms of IRBP1177-1191. From Day 0 until the end of the experiment, animals were scored twice weekly for clinical signs of anterior and posterior uveitis. On Day 28, animals were culled and eyes (right and left) were dissected out, transferred in tissue fixative then processed for paraffin embedding and stored in paraffin blocks for optional histopathology analysis.

Treatment groups and dosages

All experimental groups were $n=12$

- 25 The administration volume was 5 ml/kg for PO administration and 100 μl fixed volume per rat for SC administration.

Table 5

	Group	Treatment			Disease Induction
		Dose	Route	Regimen	
1	Vehicle	n/a	SC	13 doses*	Day 0: 100 μg

2	Cyclosporin A	20 mg/kg	PO	SID, Day 0-Day 27	huMBP
3	ATX peptides	0.1-100 µg	SC	13 doses*	
4	Vehicle	n/a	SC	13 doses*	Day 0: 100 µg huMBP and 20 µg IRBP
5	Cyclosporin A	20 mg/kg	PO	SID, Day 0-Day 27	
6	ATX peptides	0.1-100 µg	SC	13 doses*	

n/a: not applicable, IRBP, interphotoreceptor binding protein; huMBP, human myelin basic protein; CFA, complete Freund's adjuvant; SC, subcutaneous injection; PO, *per os*, oral gavage; SID, *semel in die*, once daily

- 5 *ATX peptides or vehicle were administered on the following days and at the following doses: 0.1 µg/rat on Day -22, 1 µg/rat on Day -20, 10 µg/rat on Day -18, 100 µg/rat on Days -15, -13, -11, -8, -6, -4, 3, 10, 17 and 24.

Readouts

10 **Non-specific clinical observations**

From Day 0 until the end of the experiment, animals were checked daily for non-specific clinical signs to include abnormal posture (hunched), abnormal coat condition (piloerection) and abnormal activity levels (reduced or increased activity).

- 15 Animals were culled prior to the scheduled end of the study if non-specific clinical signs were judged too severe.

Bodyweights

From Day 0 until the end of the experiment, animals were weighed daily.

20

Clinical scores (Uveitis)

From Day 0 until the end of the experiment, animals were scored twice per week by a single operator blind to treatment for clinical signs of ocular inflammation (anterior uveitis) using the following scoring system: (0) normal, (1) slight iris vessel dilation

and thickened iris stroma, a few scattered inflammatory cells, or both, (2) engorged blood vessels in the iris, abnormal pupil contraction and (3) hazy anterior chamber. Data were graphed (Mean \pm SEM).

5 Table 6

Anterior uveitis scoring:

	Description
0	Normal
1	Slight iris vessel dilation and thickened iris stroma, a few scattered inflammatory cells
2	Engorged blood vessels in the iris, abnormal pupil contraction
3	Hazy anterior chamber

10 From Day 0 until the end of the experiment, animals were scored twice per week by a single operator blind to treatment for clinical signs of posterior uveitis. Retinal images were captured using TEFI in non-anaesthetised but restrained animals following pupil dilatation using Tropicamide 1% then Phenylephrine hydrochloride 2.5%. Retinal images were scored using the modified scoring system described below with a maximum possible score of 10. Data were graphed (Mean \pm SEM).

15

Table 7

Posterior/intermediate uveitis scoring:

Criteria	
Retinal vessels	
1	1 vessel engorged
2	More than 1 vessel engorged
3	All main vessels engorged
4	Not visible due to 'white-out'
Retinal tissue Infiltration	
1	1-2 small areas of retinal damage
2	3+ small areas or 1+ large area

3	Widespread damage
4	Not visible (white-out or severe detachment)

Structural damage[†]

1	Retinal detachment with folding
2	Not visible (white-out or severe detachment)

[†] Posterior uveitis was ultimately scored without taking into account structural damage as it was not applicable.

RESULTS

Non-specific clinical observations

- 5 From Day -22 until the end of the experiment, animals did not show any non-specific clinical signs.

Bodyweights

Bodyweights for huMBP and huMBP + IRBP models, expressed as a percentage of the initial (Day -22) bodyweights, were analysed by two-way ANOVA followed by Dunnett's *post*-test for multiple comparisons between experimental groups and vehicle group. Two-way ANOVA revealed a significant effect of time and treatment in both huMBP and huMBP + IRBP models (all $p < 0.0001$). In the huMBP model, Dunnett's *post*-test revealed a significant increase in bodyweight on Days 22, 24 and 15 28 in the Cyclosporin A group (all $p < 0.05$) and in the ATX peptides group ($p < 0.05$, $p < 0.05$ and $p < 0.01$, respectively) vs. vehicle group. In the huMBP + IRBP model, Dunnett's *post*-test revealed a significant increase in bodyweight on Days 13, 15, 22, 24 and 28 in the Cyclosporin A group ($p < 0.05$, $p < 0.05$, $p < 0.05$, $p < 0.01$ and $p < 0.01$, respectively) vs. vehicle group.

20

Anterior uveitis clinical scores

Animals with an average total score (average of left eye plus right eye) of 1 on two consecutive occasions or >1 after any TEFI session were considered to have developed clinical signs of anterior uveitis. Anterior uveitis clinical scores were analysed by two-way ANOVA followed by Dunnett's *post*-test for multiple comparisons between experimental groups and vehicle group. In the huMBP model, all mice displayed no clinical signs of anterior uveitis throughout the course of the study. In the huMBP + IRBP model, a two-way ANOVA revealed a significant effect

25

of time and treatment (both $p < 0.0001$). A Dunnett's *post-test* revealed a significant improvement in clinical scores in the Cyclosporin A group on Days 7, 10, 14, 17, 21 and 28 ($p < 0.05$, $p < 0.0001$, $p < 0.0001$, $p < 0.0001$, $p < 0.0001$ and $p < 0.05$, respectively) and in the ATX peptides group on Day 10 ($p < 0.0001$) vs. vehicle group (Fig. 7A). An unpaired two-tailed two-sample Student's *t*-test of area under the curve (AUC) analysis of anterior uveitis clinical score data revealed a significant effect of Cyclosporin A ($p < 0.0001$) and ATX peptides vs. vehicle ($p < 0.05$) (Fig. 7B).

10 Posterior/intermediate uveitis clinical scores

Animals with an average total score (average of left eye plus right eye) of 1 on two consecutive occasions or >1 after any TEFI session were considered to have developed clinical signs of posterior uveitis. Posterior uveitis clinical scores were analysed by two-way ANOVA followed by Dunnett's *post-test* for multiple comparisons between experimental groups and vehicle group. In the huMBP model, a two-way ANOVA revealed a significant effect of time and treatment (both $p < 0.0001$). A Dunnett's *post-test* revealed a significant improvement in clinical scores in the Cyclosporin A group on Days 7, 10, 14, 17, 21, 24 and 28 ($p < 0.05$, $p < 0.0001$, $p < 0.0001$, $p < 0.0001$, $p < 0.01$ and $p < 0.05$, respectively) and in the ATX peptides group on Days 7, 10, 14, 17, 21, 24 and 28 ($p < 0.05$, $p < 0.0001$, $p < 0.0001$, $p < 0.0001$, $p < 0.01$ and $p < 0.05$, respectively) vs. vehicle group (Fig. 8A). In the huMBP model, an unpaired two-tailed two-sample Student's *t*-test of area under the curve (AUC) analysis of posterior uveitis clinical score data revealed a significant effect of Cyclosporin A ($p < 0.0001$) and ATX peptides ($p < 0.0001$) vs. vehicle (Fig. 8B).

In the huMBP + IRBP model, a two-way ANOVA revealed a significant effect of time and treatment (both $p < 0.0001$). A Dunnett's *post-test* revealed a significant improvement in clinical scores in the Cyclosporin A group on Days 7, 10, 14, 17 and 21 ($p < 0.05$, $p < 0.0001$, $p < 0.0001$, $p < 0.0001$ and $p < 0.05$, respectively) and in the ATX peptides group on Day 10 ($p < 0.01$) vs. vehicle group (Fig. 8C). An unpaired two-tailed two-sample Student's *t*-test of area under the curve (AUC) analysis of posterior uveitis clinical score data revealed a significant effect of

Cyclosporin A vs. vehicle ($p < 0.0001$) (Fig. 8D). An unpaired one-tailed two-sample Student's *t*-test of area under the curve (AUC) analysis of posterior uveitis clinical score data revealed a significant effect of ATX peptides vs. vehicle ($p < 0.05$) (Fig. 8D).

5

Incidence of posterior/intermediate uveitis

Animals with an average total score (left eye plus right eye) of one on two consecutive occasions or >1 after any TEFI session were considered to have developed clinical signs of posterior uveitis.

10

In the huMBP model, animals treated with Cyclosporin A and ATX peptides had reduced incidence compared to vehicle-treated animals (Fig. 9A). Only one animal treated with Cyclosporin A and three animals treated with the ATX peptides went on to develop clinical signs of EAU (see Table 8).

15

Table 8

Group	Incidence of uveitis	Onset (Day)	Mean Maximum Score
huMBP, Vehicle	100% (12/12)	10.4 ± 1.3	1.8 ± 0.07
huMBP, Cyclosporin A	5% (1/12)	3	1.2 ± 0.7
huMBP, ATX peptide	25% (3/12)	8 ± 1	1.08 ± 0.2 ^s
huMBP/IRBP, Vehicle	100% (12/12)	7.7 ± 0.8	7.9 ± 0.08
huMBP/IRBP, Cyclosporin A	100% (12/12)	12.8 ± 0.7	6.1 ± 0.5
huMBP/IRBP, ATX peptide	100% (12/12)	10.3 ± 0.3	7.9 ± 0.08

^s For animal 3.10, score of 4 (average of left and right eye score) on Day 21 was not included into data analysis (outlier identified analysing Day 21 posterior uveitis clinical score data with Grubb's test with $\alpha = 0.05$)

20

In the huMBP + IRBP model, Cyclosporin A significantly delayed the onset of posterior uveitis if compared to the vehicle-treated group ($p < 0.0001$) (Fig. 9B). ATX peptides significantly delayed onset of posterior/intermediate uveitis compared to vehicle-treated group ($p < 0.05$) (Fig. 9B).

5

CONCLUSIONS

Administration of huMBP alone or combined with IRBP induced clinical signs of posterior uveitis resulting in enlarged blood vessels, retinal inflammation and cellular infiltration, as expected in these models of EAU. Clinical signs of posterior uveitis were less severe in the huMBP model compared to animals receiving huMBP + IRBP.

10

Clinical signs of anterior uveitis were observed in the huMBP + IRBP model but not in the huMBP model. In the huMBP + IRBP model, clinical signs of anterior uveitis included increased vascularisation of the iris and cellular infiltration of the anterior chamber as well as abnormal pupil contraction.

15

Overall, in the huMBP + IRBP model, Cyclosporin A and ATX peptides significantly reduced the clinical signs of anterior uveitis.

20

In the huMBP model, Cyclosporin A and ATX peptides reduced the incidence of posterior uveitis compared to vehicle-treated animals.

Cyclosporin A and ATX peptides significantly delayed the onset of posterior uveitis in the huMBP + IRBP model, when compared to the vehicle-treated group.

25

Overall, in the huMBP and huMBP + IRBP models, Cyclosporin A and ATX peptides significantly reduced clinical signs of posterior/intermediate uveitis.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be

30

understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, cellular immunology or related fields are intended to be within the scope of the following claims.

5

CLAIMS

1. A composition which comprises a myelin basic protein peptide selected from the following:

- 5 MBP 30-44 (SEQ ID NO:1);
MBP 83-99 (SEQ ID NO:2);
MBP 131-145 (SEQ ID NO:3); and
MBP 140-154 (SEQ ID NO:4)

for use in treating or preventing uveitis in a subject.

10

2. A composition for use according to claim 1 wherein said composition comprises:

- MBP 30-44 (SEQ ID NO:1);
MBP 83-99 (SEQ ID NO:2);
15 MBP 131-145 (SEQ ID NO:3); and
MBP 140-154 (SEQ ID NO:4).

3. A composition for use according to claim 1, wherein the uveitis is posterior uveitis, anterior uveitis or intermediate uveitis.

20

4. The use of composition as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment and/or prevention of uveitis in a subject.

5. The use according to claim 4, wherein the uveitis is posterior uveitis, anterior
25 uveitis or intermediate uveitis.

6. A method for treating or preventing uveitis in a subject which comprises the step of administration of a composition as defined in claim 1 or claim 2 to the subject.

30 7. A method according to claim 8, wherein the uveitis is posterior uveitis, anterior uveitis or intermediate uveitis.

8. A kit which comprises a myelin basic protein peptide selected from the following:

MBP 30-44 (SEQ ID NO:1);
MBP 83-99 (SEQ ID NO:2);
MBP 131-145 (SEQ ID NO:3); and
MBP 140-154 (SEQ ID NO:4)

5 for use in the treatment of prevention of uveitis in a subject.

9. A kit for use according to claim 8 wherein said kit comprises MBP 30-44 (SEQ ID NO:1);

MBP 83-99 (SEQ ID NO:2);
MBP 131-145 (SEQ ID NO:3); and
10 MBP 140-154 (SEQ ID NO:4).

10. A kit for use according to claim 9 wherein said MBP peptides are for simultaneous, separate or sequential administration.

15 11. An animal model of uveitis wherein the animal has been immunised with human MBP and interphotoreceptor retinoid binding protein (IRBP) peptide.

12. An animal model according to claim 11 wherein said uveitis is posterior uveitis, anterior uveitis or intermediate uveitis.

20 13. An animal model according to claim 11 or 12 wherein the MBP is human MBP and the IRBP is bovine IRBP.

14. An animal model according to any one of claims 11 to 13 wherein the MBP and IRBP are administered by subcutaneous injection.

15. An animal model according to any one of claims 11 to 14 wherein the animal is a rat.

25 16. An animal model according to claim 15 wherein the rat is a Lewis rat.

17. An animal model according to claim 16 wherein the Lewis rat is a female Lewis rat.

FIGURE 1




FIGURE 2




FIGURE 3







FIGURE 4




Score 0




Score 1




Score 2




Score 3




Score 4




Score 5



Score 6



Score 8



Score 10

FIGURE 5




FIGURE 6





FIGURE 7



B.




FIGURE 8






FIGURE 8 CONTINUED

B.



D.





FIGURE 9



INTERNATIONAL SEARCH REPORT

International application No PCT/IB2018/050062

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K38/00 A61K38/03 C07K14/47 ADD.				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) A61K C07K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, CHEM ABS Data				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	GRAZYNA ADAMUS ET AL: "Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 47, no. 6, 1 June 2006 (2006-06-01), page 2555, XP055454346, US ISSN: 1552-5783, DOI: 10.1167/iov.05-1242 abstract -----	1,3-8,10		
A	WO 02/077025 A1 (MATSOUKAS JOHN [GR]; APOSTOLOPOULOS VASSO [AU]; TSELIOS THEODORE [GR]) 3 October 2002 (2002-10-03) the whole document ----- -/--	1-10		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
26 February 2018	03/05/2018			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Turri, Matteo			

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2018/050062

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2009/056833 A2 (APITOPE TECHNOLOGY BRISTOL LTD [GB]; WRAITH DAVID [GB]; STREETER HEATH) 7 May 2009 (2009-05-07) sequence 1 -----	1-10
A	WO 2014/160465 A2 (COUR PHARMACEUTICALS DEV COMPANY [US]; KING NICHOLAS [AU]) 2 October 2014 (2014-10-02) sequences 1095, 63 -----	1-10
A	WO 02/16410 A2 (UNIV BRISTOL [GB]; WRAITH DAVID CAMERON [GB]; ANDERTON STEPHEN MARK [G]) 28 February 2002 (2002-02-28) claim 12 -----	1-10
A	GRAZYNA ADAMUS ET AL: "Importance of cryptic myelin basic protein epitopes in the pathogenicity of acute and recurrent anterior uveitis associated with EAE", JOURNAL OF NEUROIMMUNOLOGY, vol. 113, no. 2, 1 February 2001 (2001-02-01), pages 212-219, XP055046367, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(00)00439-2 -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2018/050062

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-10

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-10

All subject-matter relating to the peptides of SEQ ID N:1-4 to treat uveitis

2. claims: 11-17

All subject-matter relating to an animal model of uveitis

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2018/050062

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 02077025	A1	03-10-2002	CA 2445640 A1	03-10-2002
			EP 1370582 A1	17-12-2003
			US 2004072222 A1	15-04-2004
			WO 02077025 A1	03-10-2002

WO 2009056833	A2	07-05-2009	AT 518546 T	15-08-2011
			AU 2008320657 A1	07-05-2009
			CA 2703170 A1	07-05-2009
			CN 101848725 A	29-09-2010
			CY 1112620 T1	10-02-2016
			DK 2211892 T3	31-10-2011
			EA 201070541 A1	30-12-2010
			EC SP10010211 A	31-08-2010
			EP 2211892 A2	04-08-2010
			HK 1142803 A1	06-01-2012
			HR P20110724 T1	31-12-2011
			IL 204662 A	31-07-2013
			JP 5361895 B2	04-12-2013
			JP 2011500776 A	06-01-2011
			KR 20100036391 A	07-04-2010
			MY 158800 A	15-11-2016
			NZ 583924 A	29-06-2012
			PL 2211892 T3	31-01-2012
			PT 2211892 E	18-10-2011
			SI 2211892 T1	30-12-2011
			US 2010286054 A1	11-11-2010
			US 2014161832 A1	12-06-2014
			US 2016263188 A1	15-09-2016
WO 2009056833 A2	07-05-2009			
ZA 201001748 B	29-06-2011			

WO 2014160465	A2	02-10-2014	AU 2014243758 A1	17-09-2015
			CA 2903718 A1	02-10-2014
			CN 105263476 A	20-01-2016
			EP 2968160 A2	20-01-2016
			HK 1220368 A1	05-05-2017
			JP 2016515122 A	26-05-2016
			KR 20160014584 A	11-02-2016
			RU 2015142245 A	18-04-2017
			US 2015010631 A1	08-01-2015
			US 2017173071 A1	22-06-2017
WO 2014160465 A2	02-10-2014			

WO 0216410	A2	28-02-2002	AT 401343 T	15-08-2008
			AT 483729 T	15-10-2010
			AU 7863701 A	04-03-2002
			AU 2001278637 B2	25-05-2006
			BR 0113400 A	08-07-2003
			CA 2420949 A1	28-02-2002
			CN 1469883 A	21-01-2004
			CN 101633689 A	27-01-2010
			CN 102764425 A	07-11-2012
			CN 102784385 A	21-11-2012
			CY 1108558 T1	09-04-2014
			CY 1111079 T1	11-06-2015
			CY 1114808 T1	14-12-2016
			CZ 307202 B6	21-03-2018
			DK 1311542 T3	10-11-2008

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/IB2018/050062
--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		DK 1731912 T3	06-01-2014
		DK 1918298 T3	29-11-2010
		EP 1311542 A2	21-05-2003
		EP 1731912 A2	13-12-2006
		EP 1918298 A2	07-05-2008
		ES 2310558 T3	16-01-2009
		ES 2353347 T3	01-03-2011
		ES 2439899 T3	27-01-2014
		HK 1052359 A1	14-11-2008
		HK 1178437 A1	03-06-2016
		HK 1178793 A1	03-06-2016
		HU 229377 B1	28-11-2013
		HU 230233 B1	28-10-2015
		HU 0300814 A2	28-10-2003
		JP 5431628 B2	05-03-2014
		JP 2004506921 A	04-03-2004
		KR 20030062321 A	23-07-2003
		MX PA03001606 A	01-11-2004
		NO 20030790 A	22-04-2003
		NZ 523841 A	30-07-2004
		PH 12013500208 A1	20-04-2015
		PL 213585 B1	29-03-2013
		PL 215145 B1	31-10-2013
		PL 215187 B1	29-11-2013
		PL 364048 A1	13-12-2004
		PT 1311542 E	03-10-2008
		PT 1731912 E	17-12-2013
		PT 1918298 E	09-12-2010
		SI 1311542 T1	28-02-2009
		SI 1731912 T1	30-05-2014
		SI 1918298 T1	31-01-2011
		US 2003191063 A1	09-10-2003
		US 2008200368 A1	21-08-2008
		US 2013156798 A1	20-06-2013
		WO 0216410 A2	28-02-2002